Top in hem/onc: NCI director’s cancer diagnosis; financial tips for physicians
Click Here to Manage Email Alerts
National Cancer Institute Director Monica M. Bertagnolli, MD, FACS, FASCO, announced that she has been diagnosed with early-stage hormone receptor-positive, HER2-negative breast cancer.
Bertagnolli took over as National Cancer Institute (NCI) director on Oct. 3, becoming the first woman to serve in that role. She said she will continue in this role but will take leave as necessary. It was the top story in hematology/oncology last week.
The second top story was about financial tips for physicians. David B. Mandell, JD, MBA, attorney and founder of OJM Group, and Andrew Taylor, a partner and wealth advisor at OJM Group, discussed how physicians can avoid common investor mistakes in a bear market, “defined as a time when stock prices are declining and market sentiment is pessimistic.”
Read these and more top stories in hematology/oncology below:
NCI director announces breast cancer diagnosis, says prognosis ‘very favorable’
Bertagnolli released a statement announcing she has been diagnosed with breast cancer. She said the cancer appears to be confined to the breast and the prognosis is “very favorable.” Read more.
Steps to take to avoid common investor mistakes in a bear market
Through the end of September, the S&P 500 had declined three consecutive quarters and lost nearly 24% of its value. Read more.
Glofitamab shows ‘curative potential’ in relapsed/refractory diffuse large B-cell lymphoma
Patients with large B-cell lymphoma who achieved complete response at the end of glofitamab (RG6026, Genentech) treatment had durable remissions and rarely experienced off-treatment progression within 1 year of therapy, according to study results. Read more.
Efgartigimod confers rapid improvement in platelet counts in immune thrombocytopenia
Efgartigimod (argenx) demonstrated clinically significant improvement in platelet counts compared with placebo among adults with primary immune thrombocytopenia, results of the phase 3 ADVANCE IV trial showed. Read more.
Multilevel interventions needed to reduce racial disparities in clinical trial enrollment
Multilevel interventions are required to increase the rate at which Black individuals participate in hematology research studies, according to study results presented at ASH Annual Meeting and Exposition. Read more.